GlassScriptPhysician profile
Nermala Persaud
NPI 1740644137
$27,543.74
in general payments reported to CMS, 2019-2025
51 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $3,521 · 2023: $4,119 · 2024: $4,239 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Honoraria: $8,375 · Travel and Lodging: $1,296 · Education: $28.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,916.61 |
| Honoraria | $8,375.00 |
| Travel and Lodging | $1,295.58 |
| Education | $28.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $10,586.29 | 2025 | Symbravo, Auvelity |
| Abbvie INC. | $2,898.91 | 2022-2025 | |
| Ucb, INC. | $1,715.53 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Emd Serono, INC. | $1,519.25 | 2021-2025 | Mavenclad, Mavenclad |
| Lundbeck LLC | $965.44 | 2022-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $862.94 | 2023-2025 | Rexulti, Nuedexta |
| Amgen INC. | $729.50 | 2021-2025 | Uplizna, Aimovig |
| Celgene Corporation | $701.92 | 2022-2025 | Zeposia |
| Pfizer INC. | $544.53 | 2023-2025 | |
| Argenx US, INC. | $530.52 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Eisai INC. | $506.07 | 2021-2025 | |
| Neurelis, INC. | $505.08 | 2022-2025 | Valtoco |
| Csl Behring | $498.89 | 2022-2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $448.98 | 2021-2024 | Austedo Xr, Austedo |
| Genentech USA, INC. | $445.51 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nermala Persaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.